viewPharmaxis Ltd

Pharmaxis gains new substantial holder with 6.89% interest

The company is developing a pipeline of products to treat inflammation and fibrosis.

Pharmaxis' top 20 shareholders held 68.6% of the company end of 2018

Pharmaxis Ltd (ASX:PXS) has gained a substantial holder in D&A Income Limited which now holds more than 27 million Pharmaxis shares representing a 6.89% interest.

D&A initially held abut 8 million shares but purchased a further 19.1 million late last month for a cash consideration of more than $5 million.


Pharmaxis is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.

The company’s development pipeline focuses on its expertise in amine oxidase chemistry and includes:

  • A series of lysyl oxidase like 2 (LOXL2) inhibitors targeting fibrotic diseases of the liver, heart, kidney and lunch that recently completed phase-one clinical trials;

  • A lysyl oxidase (LOX) inhibitor in development for pancreatic cancer that recently completed preclinical development; and

  • A potent inhibitor of semicarbazide-sensitive amine oxidase (SSAO) called BI 1467335 to develop treatment for the liver-related condition non-alcoholic steatohepatitis (NASH) and other inflammatory diseases.

Pharmaxis manufactures and exports its approved products from its facility in Sydney, including Bronchitol for the treatment of cystic fibrosis and Aridol, a lung function test for asthma.

Quick facts: Pharmaxis Ltd

Price: 0.08 AUD

Market: ASX
Market Cap: $31.66 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...



Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read